Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
ReoPro Post-Approval Trials Have Cost $250 Mil. Including J&J Stent Work
May 10 1999
•
By
The Pink Sheet
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Archive
More from Pink Sheet